New study supports MHRA advice on combined oral contraceptivesBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h3305 (Published 24 June 2015) Cite this as: BMJ 2015;350:h3305
- Mira Harrison-Woolrych, senior medical assessor,
- Jane Woolley, unit manager
- 1Benefit Risk Management Group, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK
The association between combined oral contraceptives and venous thromboembolism (VTE) is not new, and Vinogradova and colleagues’ study confirms the UK regulatory position,1 supporting decisions on safe prescribing.
The authors’ conclusions are consistent with the findings of a regulatory Europe-wide review of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial